The endogenous opioid dynorphin A-( l-1 7) (Dyn A) has been implicated as a mediator of tissue damage after traumatic spinal cord injury (TSCI) and causes hindlimb paralysis when administered intrathecally.
Motor impairment following intrathecal
Dyn A is attenuated by antagonists of excitatory amino acids (EAAs); whether opioid receptors mediate such injury has been questioned.
TSCI causes various biochemical changes associated with secondary tissue damage, including alterations in tissue amino acids, phospholipids, and fatty acids. Such changes reflect injury severity and correlate with motor dysfunction.
The present studies examined whether dynorphin administration causes similar biochemical alterations and whether effects of Dyn A can be modified by treatment with opioid-receptor antagonists.
At 24 hr after intrathecal Dyn A, there were significant declines in tissue levels of glutamate, aspartate, and glycine. Increases in total free fatty acids were found at 2 and 24 hr, reflecting changes in both saturated and unsaturated components, which were associated with significant decreases in tissue cholesterol and phospholipid phosphorus at the earlier time point. Each of these neurochemical changes, as well as corresponding motor deficits, were limited by pretreatment with the opioid antagonist nalmefene.
In separate experiments, both nalmefene and the selective K-opioid antagonist nor-binaltorphimine (nor-BNI) limited dynorphin-induced motor dysfunction; effects of nor-BNI were dose related, and those of nalmefene were stereospecific. Therefore, behavioral and neurochemical consequences of Dyn A administration are mediated in part through opiate receptors, most likely K-eceptors. These studies indicate that phospholipid hydrolysis and release of EAAs may contribute to dynorphin-induced tissue damage, suggesting for the first time a potential linkage among opioid, excitotoxin, and membrane lipid mechanisms of secondary injury after neurotrauma.
Phamacological studies with opioid-receptor antagonists support the concept that endogenous opioids contribute to the pathophysiology of tissue damage after CNS trauma (Faden et al., 1981; Flamm et al., 1982; Hayes et al., 1983; Arias, 1985; Inoue, 1986; McIntosh et al., 1987) . Dynorphin A (Dyn A), a 17-amino acid opioid peptide thought to be an endogenous ligand for the K-Opiate receptor (Chavkin and Goldstein, 198 1; Yoshimura et al., 1982) , has been implicated as a secondary injury factor after spinal cord (Faden et al., 1985) and brain trauma . Following traumatic spinal cord injury (TSCI), levels of dynorphinlike immunoreactivity increase in proportion to the degree oftrauma (Faden et al., 1985) , whereas treatment with dynorphin antiserum or K-selective opiate-receptor antagonists improve neurological recovery (Faden, 1990) .
Consistent with its putative pathophysiologic role, Dyn A and related fragments, administered intrathecally, cause chronic paralysis (Faden and Jacobs, 1984; Stevens and Yaksh, 1986) , loss of the tail-flick reflex (Herman and Goldstein, 1985) , neuroanatomical damage (Caudle and Isaac, 1987; Long et al., 1988) , and a decrease in local spinal cord blood flow (Long et al., 1987; Thornhill et al., 1989) . Effects of dynorphin on the tail-flick reflex or motor function are prevented by treatment with NMDA antagonists (Caudle and Isaac, 1988; Long et al., 1989a; Bakshi and Faden, 1990a,b) , suggesting that dynorphin-induced neurological dysfunction involves the release of excitatory amino acids (EAAs). However, the role of opiate receptors has been more controversial. Some groups have shown that opiate-receptor antagonists attenuate Dyn A-induced paralysis Spampinato and Candeletti, 1985; Faden, 1990) , whereas others have not (Herman and Goldstein, 1985; Stevensand Yaksh, 1986; Longet al., 1988 Longet al., ,1989b . In addition, nonopioid fragments of Dyn A, including Dyn A-(2-1 7) and Dyn A-(3-13), also cause paralysis, though with markedly less potency than Dyn A-( 1-17) (Faden and Jacobs, 1984; Stevens and Yaksh, 1986) . A recent report critically reviews this controversy and provides experimental evidence that both opioid and nonopioid mechanisms play a role in Dyn A-induced paralysis (Faden, 1990) .
TSCI causes increased tissue levels of free fatty acids (FFAs; Demediuk et al., 1985; Faden et al., 1987) and decreased tissue levels of EAAs . Release of FFAs after trauma reflects phospholipid hydrolysis and may contribute to subsequent tissue damage either through direct toxic effects (Chan et al., 1983) or through the actions of such metabolic products as thromboxanes (Hsu et al., 1985) . Early release of EAAs into the extracellular space after spinal cord trauma (Panter et al., 1990 ) is believed to lead to subsequent loss of total tissue levels . Pharmacological studies indicate that these EAA changes contribute to delayed tissue damage after spinal cord trauma (Faden and Simon, 1988) or brain trauma (Hayes et al., 1988; Faden et al., 1989) . The present experiments were intended to explore whether changes in FFAs and EAAs in Dyn A-induced injury parallel those after traumatic injury and whether such changes are opioid-receptor mediated.
Materials and Methods
Intrathecal infusion model. Male Sprague-Dawley rats, weighing 300-350 gm, were anesthetized with sodium pentobarbital(70 mg/kg, i.p.). An intrathecal line was implanted to the eighth thoracic vertebral level using a modification of the method of Yaksh and Rudy (1976) , as previously detailed (Bakshi and Faden, 1990a) . Briefly, polyethylene tubing (PE-10) was implanted into the subarachnoid space through the atlanto-occipital membrane and passed to T8. The catheter was then secured below the skin and the wound sutured. Animals were allowed 24 hr to recover, at which time those showing motor deficits were removed from the experiment. Agents were infused through the intrathecal catheter in a vehicle of 20 ~1 physiologic saline. Study 1. Animals were randomly assigned to pretreatment with either nalmefene (8 nmol; Key Pharmaceuticals, Miami, FL) or vehicle in a volume of 10 ~1. Fifteen minutes later, Dyn A-(1-1 7) (24 nmol; Peninsula Laboratories, Belmont, CA) or equivolume vehicle was administered. Nalmefene and Dyn A-(1-17) doses were based on previous studies (Bakshi and Faden, 1990a) and pilot data. At 2 and 24 hr after infusions, animals were reanesthetized (70 mg/kg sodium pentobarbital, i.p.) and ventilated, after laminectomy, the T7-T9 spinal cord region was frozen in situ with liquid nitrogen and the animal killed. Amino acid analysis. Free amino acids were extracted, derivatized, separated, and quantitated using a modification of the method of Allison et al. (1984) . as nreviouslv described . Sninal cord samples (20-40 mg each) were sonicated in 850 ~16.4 M pkrchloric acid and 1 .O mM EDTA, containing a-aminobutyric acid as an internal standard. The homogenate was centrifuged for 1.0 min in a Beckman Microfuge, then neutralized with 400 ~1 1.0 M potassium bicarbonate and recentrifuged for 90 sec. The supematant was removed for amino acid analysis, and the pellet was saved for protein determination using the method of Bradford (1976) . Electrochemically active derivatives of the extracted amino acids were made by mixing 20 ~1 of the extract with 100 ~1 derivatizing solution (2 ml methanol, 27 mg o-phthalaldehyde, 20 ~1 tert-butylthiol, and 4.5 ml 100 mM borax; pH, 10.0). The solution was allowed to react for 2 min, and 20 ~1 was subjected to high-performance liquid chromatography (HPLC) separation and quantitation with electrochemical detection. Integrated peak areas were used to quantitate individual amino acids. Linearity of detector response was checked with pure standards of each measured amino acid.
Free fatty acids (FFAs). Changes in FFAs were measured, as previously described (Lemke et al., 1990) . In brief, total lipids were extracted from brain tissues by homogenizing samples in 2 ml hexane:2-propanol (3:2, vol/vol; Hara and Radin, 1978; Saunders and Horrocks, 1984) . The homogenate was filtered and washed twice with 2 ml of the extracting solvent; the combined filtrate was evaporated under a stream of N,, and the lipids were redissolved in 2 ml chloroform. The lipids were then separated into fractions of 1 .O-gm Sil-LC (Sigma, St. Louis, MO) silicic acid columns. Elution was with 100 ml each of chloroform (neutral lipids) and methanol (polar lipids). Solvents were removed on a rotary evaporator, and each fraction was redissolved in 100 ~1 hexane: 2-propanol (3:2). A lo-p1 aliquot was removed from the polar liquid fraction for calorimetric determination of total lipid phosphorus as detailed by Rouser et al. (1969) . The remaining particulate matter from the homogenization was used for estimation of protein as above.
Total FFAs were separated by thin-layer chromatography (TLC) with petroleum ether : diethyl ether : acetic acid (110:90:4, by vol) as the developing solvent. Spots on TLC were visualized under UV after spraying with a solution of 2-p-toluidinyl napthalene-6-sulfonate (Jones et al., 1982) . Lipid bands were scraped from the plates prior to analysis. Cholesterol, in the presence of silica gel, was quantitated by the method of Bowman and Wolf (1962) . FFAs were extracted from the silica gel using chloroform : methanol (2: 1, vol/vol). Silica gel was removed by filtering through 0.2-pm nylon filters into conical centrifuge tubes. A heptadecanoate internal standard was added, and the filtrate was evaporated under N,. Fatty acid methyl esters (FAMES) were prepared using a modification of the method of Allen et al. (1984) . To each centrifuge tube, 20 ~1 0.5 M NaOH, 80 J N,N-dimethyl acetamide, and 40 J methyl iodide was added, with vortexing after every addition. The reaction mixtures were then heated at 65°C for 10 min and allowed to cool. Ninety microliters pyridine was added with vortexing, and the tubes were again heated at 65°C for 10 min. After cooling, 0.8 ml 0.1 M phosphoric acid equilibrated with ethylene chloride was added, followed by 25 ~1 ethylene chloride. The tubes were vortexed for 30 set and centrifuged at 500 x g for 2 min. Two microliters of the ethylene chloride lower phase was removed with a Hamilton syringe and injected into a Perkin-Elmer Sigma 300 gas chromatograph for separation and auantitation of FAMES. A Sunelco (Bellefonte. PA) nrenacked 5% DEGS-PS (Supelcoport 100/200 mesh) column was 'used wi<h N, as the carrier gas for all gas-liquid chromatography experiments. The initial column temperature was 180°C and was linearly increased at a rate of 4"C/min. The injector and flame-ionization detector temperatures were set at 250°C. Detector linearity was checked with known standards. Chromatograms were recorded, and peak areas were calculated using the chromatographic data station listed above.
Neurologic assessment. At 60 min and 24 hr after infusions, surviving animals were blindly scored for neurological function, including scores of motor function and ability to maintain position on an inclined plane. Motor function was graded on an S-point ordinal grading scale, as follows: 0, no hindlimb movement; 1, minimal movement; 2, full flexion but cannot support weight; 3, supports weight but unable to walk; 4, walks with severe spasticity and ataxia; 5, walks with moderate spasticity and ataxia; 6, walks with mild spasticity and ataxia; 7, normal. Neuroscores were also categorized and compared by functional ability in terms of walkers (4-7) or nonwalkers (O-3). For inclined plane evaluation, animals were placed horizontally on the incline in 2 orientations: left-facing and right-facing, as previously detailed (Rivlin and Tator, 1977) . The maximum angle was noted and subtracted from scores generated just prior to infusion of compounds. For each time point, a composite angle-board score was calculated by averaging the right-facing and left-facing angle change.
Statisticalanalysis. Changes in FFAs, cholesterol, phospholipid phosphorus, amino acids, and angle-board measurements were evaluated using analysis of variance (ANOVA) followed by individual post hoc comparisons (Fisher's), survival rates and walkers versus nonwalkers by Fisher's exact probability test, and neuroscores by a Kruskal-Wallis ANOVA followed by Mann-Whitney U tests. In all cases, a p value less than 0.05 was considered statistically significant.
Results

Study 1
Free fatty acids (FFAs) Dyn A caused significant increases in total FFAs, at both 2 and 24 hr after infusion (Fig. 1) . At 2 hr, changes were comprised of significant increases in the unsaturated species 18: 1, 18:3, and 22:6 and the saturated species 16:0 and 18:0 (Fig. 2) and of modest increases in 20:5 (not shown). At 24 hr, total changes reflected significant increases in the unsaturates 18: 1, 18:3, and 205 and the saturates 16:0 and 18:0 (Fig. 3) and modest increases in 20:4, 22:4, and 22:6 (not shown). Pretreatment with nalmefene significantly attenuated the increases in total FFAs at 2 and 24 hr, as well as the individual increases in 16:0, 18: 0, 18: 1, 18:3, 22:6 (Figs. l-3 ), and 22:4 (not shown).
Cholesterol and phospholipid phosphorus At 2 hr postinfusion, Dyn A caused significant declines in cholesterol and phospholipid phosphorus (as compared to vehicle controls), which partially resolved by 24 hr. The declines were significantly attenuated by nalmefene (Fig. 4) . 
Amino acids
Twenty-four hr after infusion, Dyn A-( I-17) caused significant decreases in total tissue levels of aspartate, glutamate, and glytine (Fig. 5 ), but only modest decreases in serine, GABA, glutamine, alanine, and taurine (data not shown). The changes in aspartate, glutamate, and glycine were limited by pretreatment with nalmefene (Fig. 5) . Blockade of Dyn A-induced efects Intrathecal infusion of 24 nmol Dyn A produced flaccid hindlimb weakness by 5, min, resulting in either severe (28%) or moderate (22%) paralysis or death (50%) by 24 hr (Figs. 6, 7) . Nalmefene or nor-BNI limited these effects: each compound significantly improved hindlimb function measured by neuroscore (Fig. 6 ), walking ability (Fig. 7, middle panel) , and angleboard score (Fig. 7, lower panel) , as compared to vehicle-pretreated controls. Effects of nalmefene were stereospecific: (-)nalmefene, but not (+)nalmefene, showed significant protection. Actions of nor-BNI were dose related: 20 and 35 nmol significantly improved neuroscores at both 60 min and 24 hr, whereas the 50-nmol dose did not (Fig. 6) ; the 2 lower doses (Fig. 7) . Additionally, nalmefene (stereospecifically) and nor-BNI (35 and 50 nmol) improved survival rate (Fig. 7 , upper panel).
Discussion
Dyn A caused sustained increases in FFAs, as well as early declines in tissue phospholipid and cholesterol content. These changes likely reflect membrane lipid hydrolysis, which has been well described after TSCI (Demediuk et al., 1985; Faden et al., 1987) . Phospholipid decomposition results in release of FFAs (Rehncrona et al., 1982) and is found after a variety of insults, including ischemia (Yoshida et al., 1982) , hypoxia (Gardiner et et al., 198 l) , and trauma . FFAs may cause cellular damage either directly or through the actions of their metabolites (Chan et al., 1983; Hsu et al., 1985) . High concentrations of FFAs may directly serve as detergents that disrupt cell membranes (Lucy, 1970) , facilitate osmotic hemolysis (Raz and Livine, 1973) , inhibit synaptosomal uptake of amino acids, reduce synaptosomal Na+,K+-ATPase activity (Rhoads et al., 1982; Faden et al., 1987) , and impair mitochondrial function (Lazarewicz et al., 1972; Wojtczak, 1976) . In addition, FFAs may contribute to freeradical-induced tissue injury, believed to be important in the pathophysiology of TSCI (Hall and Wolf, 1986) . The decrease in cholesterol may also reflect Dyn A-induced membrane breakdown. Cholesterol is known to have a condensing effect on the acyl-chain region of fluid bilayers, contributing to structural stability; a decrease in cholesterol affects the permeability of lipid bilayers to water and ions such as K+, Na+, and Ca2+ (Blok et al., 1977; HouSlay and Stanley, 1982) . Spinal cord trauma causes a decline in tissue cholesterol (Demopoulos et al., 1982; Segler-Stahl et al., 1985) , as well as changes in tissue cations (Lemke et al., 1987; Kwo et al., 1989) . Administration of Dyn A caused sustained (at 24 hr) decreases in total tissue glutamate, aspartate, and glycine, suggesting early release of these amino acids into the extracellular space followed by transport into the circulation or metabolic transformation tt tt t 7 1 . . . t ( Erecinska et al., 1984) . Spinal cord trauma causes sustained decreases in total tissue levels of glutamate and aspartate , as well as early transitory increases in extracellular concentrations of these amino acids (Panter et al., 1990) . Preliminary studies from our laboratory utilizing in vivo microdialysis indicate that Dyn A administration to the rat spinal cord causes early extracellular increases of glutamate, aspartate, and glycine (A. Faden and P. Halt, unpublished observations) . Glutamate and aspartate have a neurotoxic action that has long been recognized (Lucas and Newhouse, 1957; Olney et al., 197 1) . Among the known EAA receptors, the NMDA receptor appears to mediate this "excitotoxic" action (Olney et al., 197 1; Choi et al., 1988) . Treatment with NMDA antagonists limits tissue damage after spinal cord trauma . Extracellular increases in glycine may also contribute to excitotoxicity: studies in vitro (Johnson and Ascher, 1987) and in vivo (Danysz et al., 1989) have shown that glycine potentiates glutamate-induced and NMDA-induced responses by an allosteric binding site located on the NMDA receptor complex. The hypothesis that extracellular increases in EAA and glycine contribute to Dyn A-induced irreversible paralysis and histological damage is consistent with studies showing that NMDA receptor antagonists limit Dyn A-induced neurological dysfunction, including those acting at the glycine binding site (Bakshi and Faden, 1990b) , glutamate binding site (Caudle and Isaac, 1988; Bakshi and Faden, 1990a) , and ion channel (Long et al., 1989a; Bakshi and Faden, 1990a) .
The mechanism by which dynorphin induces NMDA-receptor-mediated actions remains speculative. Dyn A causes marked reduction in spinal cord blood how upon intrathecal administration (Long et al., 1987; Thornhill et al., 1989) . Thus, Dyn A-induced ischemia may trigger the release of EAAs, leading to biomembrane breakdown and the liberation of FFAs, activation of NMDA receptors, and cell death with subsequent functional deficits. It is also possible that Dyn A causes release of EAAs through opiate-receptor mechanisms independent of ischemia, possibly via presynaptic actions. However, the relationship between dynorphin and NMDA-receptor-mediated activity is complicated, with in vitro evidence that dynorphin may serve through "nonopioid" actions as an NMDA antagonist (Choi et al., 1989; Massardier and Hunt, 1989) .
Involvement of opiate receptors in the neurologic effects of Dyn A was first suggested by Han and Xie (1982) , who demonstrated that naloxone partially blocks the tail-flick effects of Dyn A-( l-l 3); the low efficacy of naloxone to reverse these effects and the absence of cross-tolerance between morphine analgesia and Dyn A-induced reflex loss led them to propose that Dyn A was acting not at p-receptors, but at K-receptors. Subsequently, a number of groups have demonstrated that opioid antagonists attenuate Dyn A-induced neurologic dysfunction, including the nonselective antagonist naloxone Spampinato and Candeletti, 1985) , the K-active antagonist MR1452 (Spampinato and Candeletti, 1985) , and the K-Selective antagonist nor-BNI (Faden, 1990) . In contrast, other observations suggest that the effects of Dyn A are not entirely opioid. Dyn A fragments (2-l 7) and (3-13) apparently devoid of opiate-receptor binding activity (Chavkin and Goldstein, 198 1; Walker et al., 1982) , also cause a clinically similar paralysis, though with less potency (Faden and Jacobs, 1984; Stevens and Yaksh, 1986; Long et al., 1988; Bakshi and Faden, 1990a) . Furthermore, some groups have failed to block Dyn A-induced paralysis with naloxone (Faden and Jacobs, 1984; Stevens and Yaksh, 1986; Long et al., 1988) . Long et al. (1989b) , using an anesthetized rat model involving intrathecal injection by lumbar puncture, failed to block Dyn A-induced paralysis with nor-BNI; however, only a single, relatively low dose of nor-BNI was evaluated. Because the K-agOniSt U50488H, even at high doses, does not cause alterations in motor function, some have argued that Dyn A-induced paralysis is entirely nonopioid (Stevens and Yaksh, 1986; Long et al., 1988) .
Nalmefene is an opiate-receptor antagonist with increased activity at K-Opiate receptors (Michel et al., 1985) , which is strongly neuroprotective after spinal cord trauma . Nalmefene pretreatment attenuated the lipid and amino acid changes after Dyn A infusion and stereospecifically limited the paralytic effects. In addition, the highly specific K-Opiate receptor antagonist nor-BNI (Takemori et al., 1988) which limits paralysis after spinal cord trauma (Faden, 1990) reduced Dyn A-induced motor dysfunction. Taken together, these findings strongly suggest that the consequences of Dyn A administration are, at least in part, mediated by opiate receptors, and more specifically, the K-Opiate receptor. Consistent with this hypothesis, Dyn A binds well to opiate receptors, with preference for K subtypes (Chavkin et al., 1982) ; such receptors are widely distributed in the spinal cord (Traynor et al., 1982; Czlonkowski et al., 1983; Mack et al., 1984; Gouarderes et al., 1985) . There is also mounting evidence to support the existence of separate populations of K-receptOrS (isoreceptors) within the CNS (Attali et al., 1982; Gouarderes and Cros, 1984; Iyengar et al., 1985; Neck et al., 1988; Zukin et al., 1988) ; therefore, Dyn A and U50488H may well be acting through different isoreceptors. At least 2 subpopulations of K-receptors have been identified in the rat spinal cord: high-affinity (K,) and low-affinity (K,) sites (Gouarderes and Cros, 1984) . Similarly, Zukin et al. (1988) have identified KI and K2 sites in the rat brain; though Dyn A and U50488H show similar potencies at K,, Dyn A is nearly 300 times more active then U50488H at the low-affinity K2 Site.
Our findings may have particular application to spinal cord or brain trauma, which cause the accumulation of immunoreactive Dyn A (Faden et al., 1985; McIntosh et al., 1987) and a decrease in blood flow (Young et al., 1981; McIntosh et al., 1987) , as well as the release of FFAs and EAAs Panter et al., 1990) . Neurological dysfunction after such injuries can be limited by treatment with Dyn A antiserum (Faden, 1990) , NMDA antagonists (Faden and Simon, 1988) or opiate antagonists . The similar neurochemical, physiological, and pharmacological profiles between dynorphin-induced and traumatic spinal cord injuries strengthen the hypothesis that endogenous dynorphin is a secondary injury factor, contributing to the pathogenesis of CNS trauma. These studies also suggest that dynorphin-induced tissue damage may result, in part, from the release of EAAs and phospholipid hydrolysis, providing a potential linkage among opioid, excitotoxin, and membrane lipid mechanisms of secondary injury after neurotrauma.
